N064A (Alliance): Phase II Study of Panitumumab, Chemotherapy, and External Beam Radiation in Patients with Locally Advanced Pancreatic Adenocarcinoma

BACKGROUND: This North Central Cancer Treatment Group (NCCTG) N064A (Alliance) phase II trial evaluated upfront chemoradiotherapy incorporating the EGFR inhibitor panitumumab, followed by gemcitabine and panitumumab for unresectable, non-metastatic pancreatic cancer. METHODS: The treatment consisted...

Descripción completa

Detalles Bibliográficos
Autores principales: Halfdanarson, Thorvardur R, Foster, Nathan R, Kim, George P, Haddock, Michael G, Dakhil, Shaker R, Behrens, Robert J, Alberts, Steven R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9255975/
https://www.ncbi.nlm.nih.gov/pubmed/35285484
http://dx.doi.org/10.1093/oncolo/oyac002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9255975/
https://www.ncbi.nlm.nih.gov/pubmed/35285484
http://dx.doi.org/10.1093/oncolo/oyac002

Ejemplares similares